Pictor debuts PictImager at ADLM 2026
Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026
The product launch is a positive step for Pictor Holdings as it moves toward commercialization, potentially increasing its market presence in the proteomics space. However, the impact is limited as the platform is still in beta and for research use only.
Pictor Holdings debuted its next-generation high-resolution platform at ADLM 2026, introducing the new PictImager for scalable targeted protein analysis. The platform integrates PictArray, PictImager, and Pictorial software into a 96-well workflow. The company began beta-site engagement ahead of a planned full commercial launch later in 2026. The launch follows a peer-reviewed publication in the Journal of Immunological Methods demonstrating the performance of Pictor's targeted proteomic assay for autoimmune disease research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard